Research Paper Volume 15, Issue 22 pp 13118—13133

Clinical significance and immune landscape of angiogenesis-related genes in bladder cancer


Figure 4. Immunotherapy response in low- and high-risk bladder cancer. (A) Box plot of the relationship between risk score and immune checkpoints. (B) TIDE score in the low- and high-risk bladder cancer. (C) IPS of low- and high-risk groups in CTLA4+ PD1+ subgroup. (D, E) The genomic mutation rate in the high- and low-risk groups. (F) Kaplan-Meier survival analysis of OS in H-TMB and L-TMB groups. (G) Survival analysis of TMB combined with the risk score.